Recently published reports have suggested that antiangiogenic drugs such as sunitinib could potentiate the osteonecrosis of the jaw (ONJ) induced by bisphosphonates (BPs) and even induce this adverse effect per se. We reported a case of ONJ with renal cell carcinoma under sunitinib medication and history of BPs therapy. A 53-year-old man was referred to the oral surgery clinic complaining of painful exposed oral lesion and bone extraction from right lower jaw in the mouth. He underwent nephrectomy followed by 5 months treatment with cycles of 50 mg sunitinib (Sutent(®)) once a day for 4 weeks followed by 2 weeks drug free before lesion exposure in October 2016. However, the patient has encounter to intermittent mucositis and gingivitis in oral cavity several times. Our patient had a history of zoledronic acid (4 mg intravenously two times) administration due to primary cancer misdiagnosis. In our case, no dental procedure contributed to the occurrence of ONJ. The lesion was improved by sunitinib cessation and administration of antibiotics through 2 weeks. Mucosal injury induction as well as inhibition of angiogenic signaling pathways by sunitinib administration may have precipitated the occurrence of ONJ. In addition, a possible synergistic effect by previously BP treatment is another accused.
Journal of research in pharmacy practice. 0000 Jan [Epub]
Farzaneh Ashrafi, Ali Derakhshandeh, Bijan Movahedian, Azadeh Moghaddas
Department of Internal Medicine, Haematology Section, Isfahan University of Medical Sciences, Isfahan, Iran., Department of Oncology and Hematology, Isfahan University of Medical Sciences, Isfahan, Iran., Department of Oral and Maxillofacial Surgery, Isfahan University of Medical Sciences, Isfahan, Iran., Department of Clinical Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran.